# Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

> **NCT03996473** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 8 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY 88-8223)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03996473
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-06
- **Primary completion:** 2021-04-14
- **Final completion:** 2023-01-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** LPLV reached on 30Jan2023. Study was closed early for feasibility reasons related to enrollment of first line IO naïve patients. Safety data is consistent with the known safety profile of both drugs and no new safety issues have been observed
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03996473

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03996473, "Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03996473. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*